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Abstract Alzheimer’s disease (AD) is characterized by the
presence of senile plaques, neurofibrillary tangles, and neu-
ronal cell loss associated with membrane cholesterol re-
lease. 24S-hydroxycholesterol (24S-OH-Chol) is an enzymat-
ically oxidized product of cholesterol mainly synthesized in
the brain. We tested the hypothesis that plasma levels of this
oxysterol could be used as a putative biochemical marker
for an altered cholesterol homeostasis in the brain of AD
patients. Thirty patients with clinical criteria for AD, 30
healthy volunteers, 18 depressed patients, and 12 patients
with vascular dementia (non-Alzheimer demented) were
studied. Plasma concentrations of 24S-OH-Chol were as-
sayed by isotope dilution–mass spectrometry, cholesterol
was measured enzymatically, and apolipoprotein E (apoE)
was genotyped by polymerase chain reaction and restricted
fragment length polymorphism. The concentration of 24S-
OH-Chol in AD and non-Alzheimer demented patients was
modestly but significantly higher than in healthy controls
and in depressed patients. There was no significant differ-
ence in the concentrations of 24S-OH-Chol between de-
pressed patients and healthy controls nor between AD and
non-Alzheimer demented patients. The apoE 
 
e
 
4 allele influ-
ences plasma 24S-OH-Chol. However, this influence could
be completely accounted for by the elevated plasma choles-
terol in apoE4 hetero- or homozygotes. Plasma 24S-OH-
Chol levels correlated negatively with the severity of demen-
tia. AD and vascular demented patients appear to have
higher circulating levels of 24S-OH-Chol than depressed pa-
tients and healthy controls. We speculate that 24S-OH-Chol
plasma levels may potentially be used as an early biochemi-
cal marker for an altered cholesterol homeostasis in the
central nervous system.
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Alzheimer’s disease (AD), the most common cause of
dementia in old persons, is characterized by regional ac-
cumulation of senile plaques, neurofibrillary tangles, and
extensive neuronal cell death (1). Of all the brain regions,
the hippocampus, a region with a high density of neu-
ronal cells, seems to be the first to be affected by AD (2).
The mechanism causing neuronal cell death in AD has not
yet been defined (3). In the course of the AD-associated
neuronal degeneration, cell membrane degradation occurs
releasing cholesterol (4). One of the most important
mechanism for the elimination of brain-derived choles-
terol is its conversion into the polar metabolite, 24S-OH-
cholesterol (24S-OH-Chol) (5, 6).
There is hitherto no single satisfactory biological
marker for AD and the definitive diagnosis had to be
based on clinical symptomatology and confirmed by post-
mortem histology. Additionally, there is a considerable over-
lap in the phenomenology of disease between AD and
other pathologic conditions. Depression is often accom-
panied by cognitive deficits similar to those occurring in
AD (7) and has been discussed as a possible risk factor for
developing AD (8). Moreover, there seems to be a signifi-
cant comorbidity between depression and AD (9). This
phenomenological relationship often causes difficulties in
distinguishing between these two states especially in mild
forms of dementia.
As most of the circulating 24S-OH-Chol in the human
body originates in the brain (10), we hypothesized that
the 24S-OH-Chol plasma concentration is a peripheral in-
dicator of central neurodegeneration occurring in AD
and possibly also in other neurological diseases. In order
to assess whether 24S-OH-Chol could serve as a marker for
 
Abbreviations: AD, Alzheimer’s disease; 24S-OH-Chol, 24S-hydroxy-
cholesterol; ICD 10, International Classification of Diseases, 10th revi-
sion; MMSE, Mini Mental State Examination; CI, 95% confidence in-
terval of the mean.
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AD, we determined plasma concentrations of 24S-OH-Chol
in AD patients, in age-matched healthy volunteers, de-
pressed and non-Alzheimer vascular demented patients.
The apolipoprotein E (apoE) genotype is a well-
established risk factor for AD (11, 12). Moreover, the
apoE system is important for the distribution of choles-
terol in the brain and is partially involved in its transfer
from brain tissue to the cerebrospinal fluid and from
there to the circulation (13). AD patients, healthy con-
trols, depressed and non-Alzheimer demented patients
were therefore genotyped with respect to apoE.
We observed that serum concentrations of 24S-OH-
Chol were significantly higher in Alzheimer and vascular
demented patients than in depressed patients and
healthy controls.
MATERIALS AND METHODS
 
Participants
 
Thirty AD patients were recruited consecutively from the De-
partment of Psychiatry and Psychotherapy, University of Bonn,
after thorough clinical and neuropsychological examination,
EEG, cranial CT, and sonography of extracranial and intracranial
arteries. All patients were also evaluated by a structured psychiat-
ric interview (Composite International Diagnostic Interview)
(14). Wherever applicable, additional information was obtained
from close relatives of the patients using semistructured inter-
views. All patients fulfilled the criteria of the International Classi-
fication of Diseases, 10th revision (ICD 10) (15) for the presence
of dementia of the Alzheimer type. The severity of the dementia
was measured by the Mini Mental State Examination (MMSE).
MMSE scores can range between 0 and 30 with lower values indi-
cating more severe dementia. Thirty age-matched healthy volun-
teers from the elderly general population were recruited from an
epidemiological group. Exclusion of neurological or psychiatric
disorders and dementia in this group was made after extensive
interviews and neuropsychological testing. Depression represents
one of the most important differential diagnoses for AD in the
elderly. Therefore, 18 age-matched depressed hospitalized pa-
tients were selected as further controls. Depressed patients un-
derwent the same diagnostic evaluation as AD patients. As a
fourth group, 12 non-Alzheimer vascular demented patients
were recruited consecutively from the Department of Neurology,
University of Bonn. The description of all participants of the
study is given in 
 
Table 1.
 
 The study was carried out in accordance
with the principles of the Helsinki Declaration, the protocol was
approved by the local ethics committee, and all subjects or their
relatives gave informed consent.
 
Analysis of cholesterol and 24S-OH-Chol
 
Blood samples were taken after an overnight fast in EDTA-
containing tubes; aliquots for analysis of total plasma cholesterol
and 24S-OH-Chol were centrifuged at 2000 
 
g
 
 for 10 min and the
supernatant was stored at 
 
2
 
82
 
8
 
C. Blood samples for apoE geno-
typing were immediately frozen at 
 
2
 
82
 
8
 
C until analyzed. Plasma
concentrations of cholesterol were measured by standard enzy-
matic procedures (CHOD-PAP Method, Boehringer, Mannheim,
Germany) and plasma concentrations of 24S-OH-Chol were mea-
sured as described previously (16). Briefly, 10 
 
m
 
g tertiary buty-
lated hydroxytoluene as antioxidant and 200 ng of [23.23.24.25-
 
2
 
H
 
4
 
]24S-OH-Chol in 50 
 
m
 
l methanol as internal standard were
added to 500 
 
m
 
L of the plasma. After alkaline hydrolysis with 1 N
sodium hydroxide in 90% ethanol for 2 h at 50
 
8
 
C, the solution
was neutralized with 100 
 
m
 
L phosphoric acid (50% v/v) and the
sterols were extracted twice with 4.5 mL chloroform. The com-
bined organic phases were dried with a gentle stream of nitrogen
at 50
 
8
 
C, the residue was dissolved in 1 mL toluene and added to
an isolute silica cartridge equilibrated with n-hexane. Cholesterol
and other neutral serum sterols were eluted with 8 ml 0.5%
2-propanol–n-hexane (v:v) and the remaining oxysterols with 5
mL 30% 2-propanol–n-hexane (v:v). This fraction was dried with
a jet of nitrogen and the oxysterols were silylated by addition of 1.0
mL of a silylation reagent (dry pyridine–hexamethyldisilazane–
trimethylchlorosilane, 9:3:1, v/v/v). The solvent was evaporated
with nitrogen at 50
 
8
 
C and the residue was dissolved in 40 
 
m
 
L
n-decane. One 
 
m
 
L was injected onto an Ultra-1 dimethylsilicone
column (25 m 
 
3
 
 0.2 mm internal diameter 
 
3
 
 0.33 
 
m
 
m film thick-
ness; Hewlett-Packard, HP) in a gas chromatograph (HP 5890)
and 24S-OH-Chol was quantified by selected ion-monitoring on a
mass selective detector (HP 5972) under the same conditions as
described previously (5). Analysis of cholesterol and 24S-OH-
Chol was carried out blindly without further information con-
cerning diagnosis.
 
ApoE genotype
 
The apoE isoforms (
 
«
 
2, 
 
«
 
3, 
 
«
 
4) were determined by poly-
merase chain reaction–restriction fragment length polymor-
phism (PCR-RFLP) as described previously (17). Briefly, DNA
was extracted from blood cells according to standard protocols
and a 244 bp fragment was amplified by PCR. The PCR product
was digested with 
 
Hha
 
I and run on a 4% agarose gel. The bands
were stained by ethidium bromide and the different alleles were
distinguished as different band patterns.
 
Statistics
 
The hypothesis that patients with AD had higher plasma con-
centrations of 24S-OH-Chol was tested by ANCOVA (dependent
variable: 24S-OH-Chol; independent variables: diagnosis, sex,
and age). Plasma cholesterol concentrations served as covariate
because of the known linear relationship between plasma con-
centrations of cholesterol and 24S-OH-Chol in healthy adults
(10). Post-hoc comparisons were performed by the Bonferroni
method. A second ANCOVA was carried out with an additional
independent variable (i.e., the presence or absence of the apoE
 
e
 
4 allele). Correlations between parameters were tested by partial
correlation analysis (Pearson’s). All calculations were done with
the statistical software program of SPSS/Windows (SPSS Inc.,
Chicago, IL).
TABLE 1. Demographic data and apoE allele genotyping 
of patients and healthy subjects
 
AD
Patients
Healthy
Controls
Depressed
Patients
Vascular
Dementia
 
Total number 30 30 18 12
Sex
 
a
 
 (males/females) 11/19 16/14 4/14 5/7
Age (years)
 
b
 
Mean 
 
6
 
 SD 73 
 
6
 
 8 70 
 
6
 
 10 70 
 
6
 
 9 69 
 
6
 
 8
Range 52–87 49–91 48–86 52–81
ApoE 
 
«
 
4 allele
 
c
 
 
21/9 7/23 3/15 4/8(present/absent)
MMSE
 
d
 
Mean 
 
6
 
 SD 17 
 
6
 
 8 29 
 
6
 
 1 25 
 
6
 
 3 20 
 
6
 
 4
Range 0–26 27–30 16–27 14–25
 
a
 
x
 
2
 
 
 
5
 
 4.7, df 
 
5
 
 3, 
 
P
 
 
 
5
 
 0.19.
 
b
 
F 
 
5
 
 1.0, df 
 
5
 
 3, 
 
P
 
 
 
5
 
 0.38.
 
c
 
x
 
2
 
 
 
5
 
 19.2, df 
 
5
 
 3, 
 
P
 
 
 
5
 
 0.006.
 
d
 
F 
 
5
 
 13.7, df 
 
5
 
 3, 
 
P
 
 
 
,
 
 0.001.
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RESULTS
 
Demographic data and apoE genotypes in relation
to 24S-OH-Chol and cholesterol
 
No significant difference in concentrations of 24S-OH-
Chol was observed between different age strata nor between
males and females. The apoE 
 
e
 
4 allel was significantly more
present in the AD patient group than in the other groups
(Table 1). ANCOVA with apoE genotype as additional inde-
pendent variable (i.e., presence vs. absence of the apoE 
 
«
 
4
allele) revealed that the apoE 
 
«
 
4 allele did not influence
plasma 24S-OH-Chol (F 
 
5
 
 2.9, df 
 
5
 
 1, 
 
P
 
 
 
,
 
 0.1).
 
Cholesterol and 24S-OH-Chol
 
Plasma concentrations of cholesterol were similar in
patients and controls (
 
Table 2
 
). In agreement with our hy-
pothesis, a modest but highly significant difference in the
plasma 24S-OH-Chol concentrations was observed among
the four diagnostic groups (Table 2, 
 
Fig. 1
 
). Bonferroni-
adjusted post-hoc comparisons revealed that plasma 24S-
OH-Chol concentrations in AD and non-Alzheimer de-
mented patients were significantly higher than in healthy
controls (
 
P
 
 
 
,
 
 0.001 and 
 
P
 
 
 
,
 
 0.004, respectively) and de-
pressed patients (
 
P
 
 
 
,
 
 0.001 and 
 
P
 
 
 
,
 
 0.002, respectively)
(Fig. 1). The levels of 24S-OH-Chol did not differ between
depressed patients and healthy controls, nor between AD
and non-Alzheimer demented patients. The 95% confi-
dence intervals of the mean (CI) showed a good overlap
for cholesterol within the four different groups whereas the
corresponding intervals for 24S-OH-Chol were comparable
between healthy volunteers and depressed patients (52 to
67 ng/mL for the healthy volunteers and 44 to 64 ng/ml for
the depressed patients) and between patients with AD (69
to 81 ng/mL) and non-Alzheimer demented patients (67 to
89 ng/mL). None of the interactions between the indepen-
dent variables (such as diagnosis, sex, and age) proved to be
significant. The effect of the covariate (i.e., plasma choles-
terol concentration) was highly significant (F 
 
5
 
 26.6, df 
 
5
 
 1,
 
P
 
 
 
,
 
 0.001). In agreement, partial correlation analysis be-
tween plasma cholesterol and 24S-OH-Chol concentrations
with the diagnostic group as control variable revealed a sig-
nificant positive correlation (
 
r
 
 
 
5
 
 0.549, 
 
P
 
 
 
,
 
 0.001).
 
Severity of disease and plasma 24S-OH-Chol
 
The mean MMSE score was 17 
 
6
 
 8 (range 0–26) and of
the non-Alzheimer demented patients 20 
 
6
 
 4 (range 14–
25) (Table 1). Partial correlation analysis controlling for
age and total cholesterol revealed that plasma 24S-OH-
Chol concentration correlated positively with the MMSE
score in demented Alzheimer (
 
r
 
 
 
5
 
 0.420, 
 
P
 
 
 
,
 
 0.03), but
not in healthy volunteers (
 
r
 
 
 
5
 
 
 
2
 
0.447, P , 0.2), de-
pressed patients (r 5 20.152, P , 0.7), and not in non-
Alzheimer demented patients (r 5 0.077, P , 0.1).
DISCUSSION
The main findings of the present study are significantly
higher concentrations of 24S-OH-Chol in AD patients and
non-Alzheimer vascular demented patients compared to
depressed patients and healthy volunteers. The higher
mean levels of 24S-OH-Chol in the circulation of AD and
non-Alzheimer demented patients may reflect a higher
flux of 24S-OH-Chol from the brain caused by increased
release of membrane cholesterol occurring in the course
of the neurodegenerative process (4).
Depression is one of the most important differential
diagnoses of AD in elderly subjects and can be easily mis-
diagnosed, especially in mild forms of dementia. The dif-
ference in plasma 24S-OH-Chol concentrations between
AD and depressed patients may be of some interest from a
diagnostic point of view.
Cholesterol 24S-hydroxylase, an enzyme that is almost
exclusively located in the brain, is involved in the ste-
reospecific 24S-hydroxylation of brain cholesterol (5).
24S-OH-Chol passes the blood–brain barrier faster than
cholesterol itself. In healthy subjects, about 6 mg of this
oxysterol is transferred from the brain into the circulation
during a 24-h period (6). The close correlation between
circulating levels of 24S-OH-Chol and cholesterol may be
TABLE 2. Plasma concentrations of cholesterol and 24S-OH-
cholesterol in patients and controls
AD
Patients
Healthy
Controls
Depressed
Patients
Vascular
Dementia
Cholesterol [mg/dL]a
Mean 6 SD 237 6 35 228 6 43 221 6 44 243 6 45
Range 170–347 119–316 139–281 178–326
24S-OH-Chol [ng/mL]b
Mean 6 SD 75 6 18 60 6 21 54 6 21 78 6 20
Range 42–116 24–105 32–99 43–114
a F 5 1.2, df 5 3, P 5 0.31.
b F 5 7.9, df 5 3, P , 0.001.
Fig. 1. Plasma concentrations of 24S-OH-Chol in patients with
Alzheimer’s disease (AD), healthy volunteers (healthy), depressed
and non-Alzheimer vascular demented patients (VD).
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a consequence of the fact that cholesterol and 24S-OH-
Chol are distributed similarly in the lipoproteins (18).
The rapid transport of 24S-OH-Chol from the CNS into
the periphery may be interpreted as a neuroprotective
mechanism, as 24S-OH-Chol can exert strong neurotoxic
effects in vitro (19).
In view of the fact that there exists a transport of choles-
terol from the brain into the cerebrospinal fluid that is
mediated by apoE (20), we investigated the possibility that
the apoE genotype may be of importance for the circulat-
ing levels of 24S-OH-Chol. The apoE genotype did not con-
tribute substantially to the observed elevation of plasma
24S-OH-Chol in AD patients: the ANCOVA revealed that
the influence of apoE4 on plasma 24S-OH-Chol was com-
pletely accounted for by the elevated plasma cholesterol
in apoE4 hetero- or homozygotes.
AD patients as well as patients with vascular dementia
had higher circulating levels of 24S-OH-Chol, regardless
of the apoE genotype. This is consistent with a central
neurodegenerative process or an altered cholesterol ho-
meostasis in the central nervous system. The significant
negative correlation between plasma 24S-OH-Chol and
the severity of AD and vascular dementia supports the hy-
pothesis of 24S-OH-Chol being derived from degenerat-
ing neurons and explains the high levels of 24S-OH-Chol
in the early stages of dementia, where the rate of neurode-
generation is high and CNS atrophy is minimal.
The results of the present investigation suggest that
24S-OH-Chol may be a useful diagnostic tool, especially in
the early stages of dementia, where the differentiation be-
tween AD patients or age-related cognitively impaired sub-
jects and depressed patients is difficult. However, it is im-
portant to emphasize that the extent of the 24S-OH-Chol
elevation may change over time in different patients. Fur-
ther longitudinal studies in larger AD populations are
thus needed to evaluate whether 24S-OH-Chol is a suit-
able biochemical marker for the early detection of AD
and its progression.
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